GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Earnings per Share (Diluted)

Aprinoia Therapeutics (Aprinoia Therapeutics) Earnings per Share (Diluted) : $-0.78 (TTM As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Earnings per Share (Diluted)?

Aprinoia Therapeutics's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was $-0.26. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.78.

Aprinoia Therapeutics's EPS (Basic) for the six months ended in Jun. 2023 was $-0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.78.

Aprinoia Therapeutics's EPS without NRI for the six months ended in Jun. 2023 was $-0.27. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.80.


Aprinoia Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Aprinoia Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Earnings per Share (Diluted) Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Earnings per Share (Diluted)
-0.84 -1.01

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Earnings per Share (Diluted) - -0.49 -0.52 -0.26

Competitive Comparison of Aprinoia Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Aprinoia Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprinoia Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's PE Ratio falls into.



Aprinoia Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Aprinoia Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-28.231-0)/27.829
=-1.01

Aprinoia Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-7.185-0)/27.829
=-0.26

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Aprinoia Therapeutics  (NAS:APRI) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aprinoia Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines